FDA Approves Subcutaneous Keytruda for Broad Cancer Treatment
The FDA has approved Merck's KEYTRUDA QLEX, a subcutaneous form of pembrolizumab combined with berahyaluronidase alfa, for adults with most solid tumors, offering a faster, more convenient injection option that can be administered in as little as one minute, with comparable efficacy to intravenous pembrolizumab across 38 indications.